Prediction of Real-World Drug Effectiveness Prelaunch: Case Study in Rheumatoid Arthritis

Didden, Eva-Maria; Ruffieux, Yann; Hummel, Noemi; Efthimiou, Orestis; Reichenbach, Stephan; Gsteiger, Sandro; Finckh, Axel; Fletcher, Christine; Salanti, Georgia; Egger, Matthias

doi:10.1177/0272989X18775975

Scientific article

English

Prediction of Real-World Drug Effectiveness Prelaunch: Case Study in Rheumatoid Arthritis

ContributorsDidden, Eva-Maria; Ruffieux, Yann; Hummel, Noemi; Efthimiou, Orestis; Reichenbach, Stephan; Gsteiger, Sandro; Finckh, Axel

; Fletcher, Christine; Salanti, Georgia; Egger, Matthias

Published inMedical Decision Making, vol. 38, no. 6, p. 719-729

Publication date2018

Abstract

Decision makers often need to assess the real-world effectiveness of new drugs prelaunch, when phase II/III randomized controlled trials (RCTs) but no other data are available.

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département de médecine

Research groups

Citation (ISO format)

DIDDEN, Eva-Maria et al. Prediction of Real-World Drug Effectiveness Prelaunch: Case Study in Rheumatoid Arthritis. In: Medical Decision Making, 2018, vol. 38, n° 6, p. 719–729. doi: 10.1177/0272989X18775975

Article (Published version)

Identifiers

PID : unige:110686
DOI : 10.1177/0272989X18775975
PMID : 30074882

Journal ISSN0272-989X

479views

0downloads

Creation03/09/2018 13:57:00

First validation03/09/2018 13:57:00

Update03/02/2025 12:58:58

Status update03/02/2025 12:58:58

Last indexation03/02/2025 13:03:01

Archive ouverte UNIGE

Prediction of Real-World Drug Effectiveness Prelaunch: Case Study in Rheumatoid Arthritis

Decision makers often need to assess the real-world effectiveness of new drugs prelaunch, when phase II/III randomized controlled trials (RCTs) but no other data are available.

Technical informations